This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 26/11/2560    most recent 01.ATV.0000242904.34700.66v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zadelaar, A. S. M. Articles by Havekes, L. M. Search for Related Content PubMed PubMed Citation Articles by Zadelaar, A. S. M. Articles by Havekes, L. M. Related Collections Lipid and lipoprotein metabolism Type 2 diabetes Other Vascular biology Animal models of human disease

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2560.)
© 2006 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Dual PPAR/ Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice

A. Susanne M. Zadelaar; Lianne S.M. Boesten; J. Wouter Jukema; Bart J.M. van Vlijmen; Teake Kooistra; Jef J. Emeis; Erik Lundholm; German Camejo; Louis M. Havekes

From the Department of Cardiology (A.S.M.Z., J.W.J., L.M.H.), Leiden University Medical Center; TNO-Gaubius Laboratory (A.S.M.Z., L.S.M.B., T.K., J.J.E., L.M.H.), Biomedical Research Unit; Department of General Internal Medicine (L.S.M.B., L.M.H.), Leiden University Medical Center; Hemostasis and Thrombosis Research Center (B.J.M.vV.), Leiden University Medical Center, Leiden, The Netherlands; AstraZeneca (E.L., G.C.), Mölndal, Sweden.

Correspondence to Louis M. Havekes, TNO-Gaubius Laboratory, Biomedical Research Unit, Zernikedreef 9, 2333 CK, P. O. Box 2215, 2301 CE Leiden, The Netherlands. E-mail LM.Havekes{at}pg.tno.nl

Objective— We investigated whether the dual PPAR/ agonist tesaglitazar has anti-atherogenic effects in ApoE*3Leiden mice with reduced insulin sensitivity.

Methods and Results— ApoE*3Leiden transgenic mice were fed a high-fat (HF) insulin-resistance–inducing diet. One group received a high-cholesterol (HC) supplement (1% wt/wt; HC group). A second group received the same HC supplement along with tesaglitazar (T) 0.5 µmol/kg diet (T group). A third (control) group received a low-cholesterol (LC) supplement (0.1% wt/wt; LC group). Tesaglitazar decreased plasma cholesterol by 20% compared with the HC group; cholesterol levels were similar in the T and LC groups. Compared with the HC group, tesaglitazar caused a 92% reduction in atherosclerosis, whereas a 56% reduction was seen in the cholesterol-matched LC group. Furthermore, tesaglitazar treatment significantly reduced lesion number beyond that expected from cholesterol lowering and induced a shift to less severe lesions. Concomitantly, tesaglitazar reduced macrophage-rich and collagen areas. In addition, tesaglitazar reduced inflammatory markers, including plasma SAA levels, the number of adhering monocytes, and nuclear factor B-activity in the vessel wall.

Conclusions— Tesaglitazar has anti-atherosclerotic effects in the mouse model that go beyond plasma cholesterol lowering, possibly caused by a combination of altered lipoprotein profiles and anti-inflammatory vascular effects.

We investigated whether the dual PPAR/ agonist tesaglitazar has anti-atherogenic effects in ApoE*3Leiden transgenic mice with reduced insulin sensitivity. Tesaglitazar has anti-atherosclerotic effects that go beyond plasma cholesterol-lowering. This may be caused by a combination of altered lipoprotein profiles and anti-inflammatory vascular effects.

Key Words: atherosclerosis • cholesterol • inflammation • inhibitors

This article has been cited by other articles:

				S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]

				F. Chang, L. A Jaber, H. D Berlie, and M. B. O'Connell Evolution of Peroxisome Proliferator-Activated Receptor Agonists Ann. Pharmacother., June 1, 2007; 41(6): 973 - 983. [Abstract] [Full Text] [PDF]